Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001274173-25-000175
Filing Date
2025-05-14
Accepted
2025-05-14 12:50:04
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 8706
  Complete submission text file 0001274173-25-000175.txt   10941
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Subject) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-58467 | Film No.: 25944062
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 201 BISHOPSGATE LONDON X0 EC2M 3AE
Business Address 201 BISHOPSGATE LONDON X0 EC2M 3AE 442078181818
JANUS HENDERSON GROUP PLC (Filed by) CIK: 0001274173 (see all company filings)

EIN.: 000000000 | State of Incorp.: Y9 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 6282 Investment Advice
(CF Office: 02 Finance)